Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

SignificanceS Dec. 25 at 9:54 AM

$IMUX Risk premia compress only when proof accumulates, while management calibrates resource allocation to real demand signals. Absent traction, patience will erode.

0 · Reply

SuperGreenToday Dec. 25 at 4:26 AM

$IMUX Share Price: $0.59 Contract Selected: Jul 17, 2026 $0.5 Calls Buy Zone: $0.27 – $0.33 Target Zone: $0.51 – $0.62 Potential Upside: 78% ROI Time to Expiration: 204 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BlackHoleTrader Dec. 24 at 10:22 AM

$IMUX Future price discovery depends on how strategic priorities translate into measurable operating outcomes. Execution slippage remains the dominant downside risk.

0 · Reply

landauleet Dec. 24 at 8:45 AM

$IMUX I m 100% sure there will be no RS till January lol

0 · Reply

Mattjen Dec. 23 at 10:23 PM

$IMUX can't wait to see us succeed in 2026!

1 · Reply

Big_Zack22 Dec. 23 at 7:12 PM

$IMUX anyone know what to happen after dec 24? Did they apply for an extension?

1 · Reply

Tradergrows Dec. 23 at 5:44 PM

$IMUX I’d like to take time out to congratulate Vittardio and the team on a successful 2025! Great times ahead! 🎉🎄🎶

3 · Reply

takingstock73 Dec. 23 at 4:57 PM

$IMUX last I checked the drug still works

1 · Reply

Jw242 Dec. 23 at 4:27 PM

$IMUX remind me to never again invest in a company with a scientist as the CEO

0 · Reply

Jw242 Dec. 23 at 4:05 PM

$IMUX Fart’Tardio can’t even do one pull up

0 · Reply

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 13, 2025, 6:30 AM EST - 6 weeks ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 6:30 AM EDT - 2 months ago

Immunic to Participate in Industry and Investor Conferences in November

Oct 1, 2025, 6:30 AM EDT - 3 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Sep 25, 2025, 6:30 AM EDT - 3 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 3 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 4, 2025, 6:30 AM EDT - 4 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Aug 7, 2025, 6:30 AM EDT - 5 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 24, 2025, 6:30 AM EDT - 6 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 9, 2025, 5:51 PM EDT - 7 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 5, 2025, 6:30 AM EDT - 7 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 7 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 7 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 7 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 7 months ago

Immunic, Inc. Announces Proposed Public Offering

May 2, 2025, 6:30 AM EDT - 8 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 7:30 AM EDT - 8 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 28, 2025, 2:09 AM EDT - 8 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 10, 2025, 1:00 PM EDT - 9 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 9 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 9 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 3, 2025, 6:30 AM EST - 10 months ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 10 months ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 11 months ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 4, 2025, 6:30 AM EST - 11 months ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 1 year ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 9, 2024, 8:37 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

May 8, 2024, 2:20 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

May 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in May

May 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Apr 30, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Mar 20, 2024, 6:30 AM EDT - 1 year ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Mar 7, 2024, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in March

SignificanceS Dec. 25 at 9:54 AM

$IMUX Risk premia compress only when proof accumulates, while management calibrates resource allocation to real demand signals. Absent traction, patience will erode.

0 · Reply

SuperGreenToday Dec. 25 at 4:26 AM

0 · Reply

BlackHoleTrader Dec. 24 at 10:22 AM

$IMUX Future price discovery depends on how strategic priorities translate into measurable operating outcomes. Execution slippage remains the dominant downside risk.

0 · Reply

landauleet Dec. 24 at 8:45 AM

$IMUX I m 100% sure there will be no RS till January lol

0 · Reply

Mattjen Dec. 23 at 10:23 PM

$IMUX can't wait to see us succeed in 2026!

1 · Reply

Big_Zack22 Dec. 23 at 7:12 PM

$IMUX anyone know what to happen after dec 24? Did they apply for an extension?

1 · Reply

Tradergrows Dec. 23 at 5:44 PM

$IMUX I’d like to take time out to congratulate Vittardio and the team on a successful 2025! Great times ahead! 🎉🎄🎶

3 · Reply

takingstock73 Dec. 23 at 4:57 PM

$IMUX last I checked the drug still works

1 · Reply

Jw242 Dec. 23 at 4:27 PM

$IMUX remind me to never again invest in a company with a scientist as the CEO

0 · Reply

Jw242 Dec. 23 at 4:05 PM

$IMUX Fart’Tardio can’t even do one pull up

0 · Reply

takingstock73 Dec. 23 at 12:46 PM

$IMUX .75 today?

2 · Reply

Johnnyb1973 Dec. 23 at 11:03 AM

$IMUX I'm only down 20%! LFG!

2 · Reply

OfficialStocktwitsUser Dec. 23 at 6:12 AM

$IMUX RSI: 39.48, MACD: -0.0413 Vol: 0.05, MA20: 0.65, MA50: 0.72 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply